Faigel Douglas O, Lieberman David A, Weinstein Wilfred M, Fanning Shane, Fennerty M Brian, Sampliner Richard B
Portland VA Medical Center, Oregon Health and Science University, Portland, Oregon, 97201, USA.
Gastrointest Endosc. 2002 Jan;55(1):23-6. doi: 10.1067/mge.2002.120100.
Restoration of squamous epithelium in patients with Barrett's epithelium may be achieved by treatment with a proton pump inhibitor plus selective electrocoagulation of the metaplastic epithelium. The effect of such treatment on esophageal wall thickness and morphology, as determined by EUS, is unknown.
Patients with Barrett's esophagus were treated with omeprazole (40 mg by mouth, twice daily) and underwent selective multipolar electrocoagulation of the metaplastic segment monthly until complete squamous re-epithelialization or a maximum of 6 treatments was achieved. EUS was performed before and 6 months after the end of treatment. Four-quadrant large-forceps biopsy specimens were taken every 2 cm at the 6-month follow-up.
Twenty-five patients with Barrett's epithelium (mean length 3.1 cm, range 2-6 cm) were included. Complete endoscopic reversal was achieved in 24 patients. Residual intestinal metaplasia beneath squamous epithelium was observed in 1 patient. In 4 patients there was intestinalized mucosa at the neosquamocolunmar junction. The thickness of the treated distal esophageal wall decreased from 4.0 +/- 0.1 mm to 3.7 +/- 0.1 mm (mean +/- SEM; p < 0.05, 2-tailed paired t test). Untreated (control) esophageal wall thickness at the level of the aortic arch (2.1 +/- 0.1 mm vs. 2.2 +/- 0.1 mm) and the mid-body gastric wall thickness (2.9 +/- 0.1 mm vs. 3.1 +/- 0.1 mm) did not change. Among the 6 patients with residual intestinal metaplasia there was no change in mean wall thickness (3.7 +/- 0.2 mm vs. 3.8 +/- 0.2 mm); among the 19 without metaplasia, thickness decreased from 4.1 +/- 0.2 mm to 3.6 +/- 0.2 mm; p < 0.01. Of 11 patients with a decrease in wall thickness, only 1 had residual intestinal metaplasia. No changes in the 5-layer sonographic pattern of the esophageal wall were observed.
Multipolar electrocoagulation of Barrett's esophagus results in a slight decrease in thickness of the treated esophageal wall. A decrease in wall thickness by EUS was associated with the absence of intestinal metaplasia in follow-up biopsy specimens.
对于患有巴雷特食管上皮化生的患者,通过质子泵抑制剂治疗加化生上皮的选择性电凝术可实现鳞状上皮的恢复。这种治疗对食管壁厚度及形态的影响(由超声内镜测定)尚不清楚。
巴雷特食管患者接受奥美拉唑治疗(口服40毫克,每日两次),并每月对化生段进行选择性多极电凝术,直至完全鳞状上皮重新化生或最多进行6次治疗。在治疗结束前及结束后6个月进行超声内镜检查。在6个月随访时,每2厘米取四象限大钳活检标本。
纳入25例患有巴雷特食管上皮化生的患者(平均长度3.1厘米,范围2 - 6厘米)。24例患者实现了完全内镜逆转。1例患者在鳞状上皮下观察到残留肠化生。4例患者在新鳞状柱状交界处存在肠化生黏膜。治疗后远端食管壁厚度从4.0±0.1毫米降至3.7±0.1毫米(平均值±标准误;p<0.05,双侧配对t检验)。主动脉弓水平未治疗(对照)的食管壁厚度(2.1±0.1毫米对2.2±0.1毫米)及胃体中部胃壁厚度(2.9±0.1毫米对3.1±0.1毫米)未改变。6例有残留肠化生的患者平均壁厚度无变化(3.7±0.2毫米对3.8±0.2毫米);19例无化生的患者,厚度从4.1±0.2毫米降至3.6±0.2毫米;p<0.01。在11例壁厚度减小的患者中,只有1例有残留肠化生。未观察到食管壁五层超声图像模式的变化。
巴雷特食管的多极电凝术导致治疗的食管壁厚度略有减小。超声内镜显示的壁厚度减小与随访活检标本中无肠化生相关。